GlobeStar Therapeutics Corp (GSTC)

[sharky]

Phase III on her way, From June 18th PR:


The regulatory firm will begin with a presubmission meeting with the FDA biologic group to obtain a regulatory strategy consensus with the FDA for authority to proceed. The objective is agreement for the protocol for the third and final clinical trial.

Our patented drug, Liprostin™, has completed the Phase II Clinical Study for treatment of Peripheral Arterial Disease (PAD) that often results in amputation as treatment. Liprostin™ is believed to reduce walking pain, treat diabetic ulcerations and reduce inflammation.



4 months ago, getting ready for updates IMO



$SOAN